Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Brodeur GM1, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al.Journal of Clinical Oncology, 1993, Aug 11http://www.ncbi.nlm.nih.gov/pubmed/8336186Many papers have been published from the INSS/ INRG meetings that were initiated from the first Forbeck meeting in 1985 and follow up meetings. Currently the INRGdb has many papers each year published.

Results for Patients

Our work with Kris Sariosek and his mentor, Anthony Letai, has led to current efforts to initiate a clinical trial involving combined JAK and BCL-XL inhibition for the treatment of JAK2-mutant myelofibrosis (refer to Winter et al, Science Signaling 2014 paper above).

— Kris Cameron Wood, Ph.D., Duke University

The concept of the international staging system for neuroblastoma, and subsequent international standards of risk evaluation really grew out of the very 1st Forbeck Foundation meeting. This was a very good thing. I should note that a highly-successful large clinical trial in neuroblastoma, that impacted standard-of-care therapy would not have occurred without help from Jennifer and George Forbeck. Their invaluable assistance, which was provided outside of the context of the Forbeck Foundation, was key to enabling a study that resulted in a New Eng J of Medicine article that reported data which has impacted many hundreds of children with neuroblastoma and will continue to do so in the future.